Cannabis Experts Join True Leaf Team for Final Marijuana Licensing Review Stage

VANCOUVER, BC / April 24, 2017 / True Leaf Medicine Inc. (True Leaf), a division of True Leaf Medicine International Ltd. (CSE:MJ) (TLA.F), has engaged a number of cannabis experts to guide the company through the final stage in Health Canada's review of its application for a license to produce marijuana in Canada.
 
Experts from industry-leading Pipe Dreemz Inc., Protect-IP Global Solutions Inc., Eurofins Scientific, and Ample Organics will be working with True Leaf over the next few weeks to prepare a review package for submission to Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR) application process.
 
Health Canada recently upgraded the Marihuana for Medical Purposes Regulations (MMPR) application process to the ACMPR licensing program, so the experts will be working with True Leaf to update its original MMPR application to ensure True Leaf meets or exceeds the new compliance measures.
Read more: True Leaf Medicine Inc ( MJ )

True Leaf Close to Completing Process for Marijuana License True Leaf Reaches Stage Five, Last Stage Before Pre-License Inspection 2017-04-20 08:32 ET

Vancouver, British Columbia--(April 20, 2017) - True Leaf Medicine Inc. (CSE: MJ) (FSE: TLA) ("True Leaf"), a division of True Leaf Medicine International Ltd., is two steps away from completing the process to acquire a license to produce and grow marijuana in Canada. True Leaf is now proceeding to stage five of the process, the 'Review', two years after submitting its application to Health Canada.
 
True Leaf is one out of over 100 companies that currently have applications in the review stage for a license to produce marijuana, out of a total of 1,630 applications received by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Today, there are just 43 licensed producers in Canada.
Read more: True Leaf Medicine ( MJ )

Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec

OTTAWA, ONTARIO--( April 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra") (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. ("Aphria") (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec. 
 
Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer's licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra's third quarter of 2017 and Aphria's first quarter of 2018.
Read more: Tetra Bio-Pharma ( TBP )

Invictus MD Announces OptionCo Has Received its License to Cultivate under ACMPR

VANCOUVER, March 30, 2017 - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (CSE: IMH; OTC: IVITF; FRA: 8IS) announces that OptionCo has received its license to cultivate under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") as Acreage Pharms Ltd. ("Acreage Pharms").
 
"This is a historic day for our Company, our sector and investors," said Dan Kriznic, Chairman & CEO, Invictus MD. "We are Canada's Cannabis Company. We now have 250 acres of cultivation space that stretches from Alberta to Ontario. Alberta has low cost of production as a result of low energy and water costs. The property is friendly to building as many square feet as required based on the significant demand. The CEO of Acreage Pharms is a serial entrepreneur and has been successful in previous ventures. He will be a key addition to the Invictus MD team. As one of the few cannabis producing companies in North America approved under the ACMPR this will enable us to engage and satisfy a wider investor audience, strengthening the sector and bring Invictus MD to international institutional investors." 
Read more: Invictus MD Strategies Corp ( IMH )

Aurora Cannabis to be Cornerstone Investor in Australian Medical Cannabis IPO

Acquiring 19.9% Stake in Cann Group Limited ---  Australia's First Medical Cannabis Licensed Producer
 
VANCOUVER, March 28, 2017 - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that it has committed to taking part in the initial public offering ("IPO") of Cann Group Limited ("Cann Group") on the Australian Stock Exchange ("ASX") as the cornerstone investor, securing a 19.9% stake in Cann Group, the first company in Australia ever to be licenced for research and cultivation of medical cannabis for human use.
Read more: Aurora Cannabis Inc ( ACB )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker